Allurion Technologies Inc. provides a weight loss platform aimed at treating obesity. Its primary customers include individuals seeking weight loss solutions and healthcare providers offering obesity management services. Revenue is generated from the sale of its Allurion Balloon, which is a swallowable intragastric balloon, and subscriptions to its Virtual Care Suite, which includes remote monitoring and telehealth services. The Allurion Balloon accounts for approximately 70% of revenue, while the Virtual Care Suite contributes around 30%. Factors supporting endurance include the growing prevalence of obesity and increasing acceptance of non-invasive weight loss solutions. However, competition from other weight loss programs and medical devices could limit its market share.
—
Allurion Technologies Inc. provides a weight loss platform aimed at treating obesity. Its primary customers include individuals seeking weight loss solutions and healthcare providers offering obesity management services. Revenue is generated from the sale of its Allurion Balloon, which is a swallowable intragastric balloon, and subscriptions to its Virtual Care Suite, which includes remote monitoring and telehealth services. The Allurion Balloon accounts for approximately 70% of revenue, while the Virtual Care Suite contributes around 30%. Factors supporting endurance include the growing prevalence of obesity and increasing acceptance of non-invasive weight loss solutions. However, competition from other weight loss programs and medical devices could limit its market share.
—
Daily adjusted close
Allurion Technologies Inc. provides a weight loss platform aimed at treating obesity. Its primary customers include individuals seeking weight loss solutions and healthcare providers offering obesity management services. Revenue is generated from the sale of its Allurion Balloon, which is a swallowable intragastric balloon, and subscriptions to its Virtual Care Suite, which includes remote monitoring and telehealth services. The Allurion Balloon accounts for approximately 70% of revenue, while the Virtual Care Suite contributes around 30%. Factors supporting endurance include the growing prevalence of obesity and increasing acceptance of non-invasive weight loss solutions. However, competition from other weight loss programs and medical devices could limit its market share.